PATENT CLAIM ANALYSIS

Application Number: 15868541
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "133100"]

Abstract:
Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.

Claim (Index 63):
The method of  claim 55 , wherein the VEGF targeting agent is bevacizumab or gemcitabine.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.96923
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15001419', '14115825', '13063402', '15509461', '14123406']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7147181231966689
- 35 USC 102 Novelty (BERT): 0.5947790515985355
- Combined Prediction Score: 0.7027242160368555
- Mean Citation Score: 346.672996
- Max Citation Score: 526.7913
- Similarity Product: 417.2356315125346

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test